<DOC>
	<DOCNO>NCT01101386</DOCNO>
	<brief_summary>This study 's primary objective determine continuous renal replacement therapy ( CRRT ) adequately remove sulfobutylether-ÃŸ-cyclodextrin sodium ( SBECD ) vehicle blood intravenous voriconazole utilize critically ill patient renal dysfunction require dialysis . Secondarily , pharmacokinetics intravenous voriconazole metabolite ( UK121-265 ) adverse effect SBECD accumulation also evaluate . The study hypothesis CRRT effective remove SBECD allow patient receive intravenous voriconazole without concern SBECD accumulation .</brief_summary>
	<brief_title>Study Cyclodextrin ( SBECD ) Voriconazole Blood Concentrations During Continuous Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients receive continuous renal replacement therapy prescribe voriconazole therapy treatment prophylaxis fungal infection . Patients expect CRRT &lt; 5 day , Patients ChildPugh C cirrhosis , Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>SBECD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Renal Failure</keyword>
</DOC>